Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Emerging oral agents for multiple sclerosis.
A Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)
Myelin Gordon Research Conference
Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
[Reduction of spastic increased muscle tone in multiple sclerosis by the nonopioid analgesic flupirtine].
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate.
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
Headwaters of the zebrafish -- emergence of a new model vertebrate.
Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis
UCSF Seminar: "Neuron-glia interactions regulate CNS node of Ranvier assembly."
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
A Complex Case of Neuro-Behçet's Disease in a Patient Previously Diagnosed with multiple Sclerosis: A Case Report.
Mylan's ANDA for Three Times Per Week Generic Copaxone® 40 mg/mL Accepted for Filing by FDA
Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy.
Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence.
Effects of fumaric acid esters on blood-brain barrier tight junction proteins.
Regulation of B cell function by the immunosuppressive agent leflunomide.
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Genpharm and Genzyme Aubagio ® agreement for the MENA region
Multiple sclerosis: association with HL-A3.
Flupirtine as Oral Treatment in Multiple Sclerosis (FLORIMS)
Dimethyl fumarate (BG-12, Tecfidera) approved for use by the NHS in Scotland

Pages